LEO Pharma Reports Positive Phase 2 Tralokinumab Results
BALLERUP, Denmark, July 9, 2026 LEO Pharma A/S has announced positive results from the Phase 2 TRAPEDS-1 clinical trial...
KEYTRUDA
Advertisement
Merck Announces Expanded FDA Approval for Keytruda in MIBC
SILVER SPRING, Maryland, July 10, 2026 Merck has received U.S. Food and Drug Administration (FDA) approval for Keytruda® (pembrolizumab)...
Pfizer Canada Secures PADCEV Plus KEYTRUDA Approval
KIRKLAND, Quebec, Canada, June 29, 2026 Pfizer Canada ULC announced that Health Canada has approved PADCEV® (enfortumab vedotin) in...
Merck Animal Health Acquires TARGAN to Advance Poultry Technology
RAHWAY, N.J., June 11, 2026 Merck Animal Health, a division of Merck & Co., Inc., has signed a definitive...
Roche Expands VENTANA MMR Companion Diagnostic Across Multiple Cancer Types
TUCSON, Arizona, USA, June 11, 2026 Roche Diagnostics has announced a significant expansion of its precision oncology diagnostics portfolio...
Advertisements
BioInvent’s TNFR2 Antibody BI-1808 Shows Promising Responses in Advanced CTCL at EHA 2026
LUND, Sweden, June 11, 2026 BioInvent International AB presented new clinical data from its ongoing Phase 2a study evaluating...
Merck and Gilead End KEYNOTE-D46 Study Update
RAHWAY, N.J. and FOSTER CITY, Calif., June 8, 2026 Merck (NYSE: MRK) and Gilead Sciences (Nasdaq: GILD) announced the...
Agilent Expands FDA-Approved PD-L1 Testing for KEYTRUDA Across Four Cancer Types
SANTA CLARA, Calif., June 2, 2026 Agilent Technologies announced that the U.S. Food and Drug Administration (FDA) has approved...
Merck’s Calderasib Earns FDA Breakthrough Therapy Status
RAHWAY, N.J., May 29, 2026 Merck (known as MSD outside the United States and Canada) has announced that the...
Virax Biolabs Reports Positive Long COVID Data
LONDON, United Kingdom, May 26, 2026 Virax Biolabs Group Limited has announced encouraging early clinical data for ViraxImmune™, its...
Advertisement
